上海微创心脉医疗科技（集团） 股份有限公司 会计师事务所选聘制度 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可比照本 制度执行。 第三条 公司选聘或解聘会计师事务所，应当经董事会审计委员会（以下简 称"审计委员会"）审议同意后，提交董事会审议，并由股东会审议决定。公司 不得在股东会审议前聘请会计师事务所开展审计业务。 第四条 公司控股股东不得向公司指定会计师事务所，不得干预审计委员会、 董事会及股东会独立履行审核职责。 二零二五年八月 上海微创心脉医疗科技（集团）股份有限公司 会计师事务所选聘制度 上海微创心脉医疗科技（集团）股份有限公司 会计师事务所选聘制度 第一章 总 则 第一条 为进一步规范上海微创心脉医疗科技（集团）股份有限公司（以下 简称"公司"）选聘（含续聘、改聘，下同）会计师事务所的行为，切实维护股 东利益，提高财务信息质量，根据《中华人民共和国公司法》《中华人民共和国 证券法》《上海证券交易所科创板股票上市规则》《国有企业、上市公司选聘 ...

Core Points - The document outlines the management system for the shares held by directors and senior management of Shanghai MicroPort MedBot (Group) Co., Ltd, aiming to enhance market order and protect investors' rights [1][2] - The system is based on relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China, as well as the rules of the Shanghai Stock Exchange [1][2] Summary by Sections General Principles - The system applies to all shares held by directors and senior management, including those in multiple accounts, and mandates compliance with insider trading regulations [2] - Prior to trading, directors and senior management must notify the board secretary in writing, who will verify the company's disclosure status [2][3] Prohibited Trading Activities - Directors and senior management are prohibited from transferring shares under specific conditions, such as within one year of the company's stock listing or within six months after leaving the company [3][4] - Trading is also restricted during certain periods, such as before the announcement of annual or quarterly reports [3][4] Information Reporting and Disclosure - Directors and senior management must report their shareholdings and any changes within two trading days through the Shanghai Stock Exchange [5][6] - The company is responsible for ensuring the accuracy and timeliness of these disclosures [5][6] Share and Account Management - Directors and senior management can only transfer up to 25% of their shares annually, with exceptions for certain legal circumstances [7][8] - New shares acquired through various means are subject to specific transfer conditions [7][8] Responsibilities and Penalties - Violations of the trading rules may result in penalties from regulatory bodies, and the company can impose internal disciplinary actions [9][10] - The company must report any illegal trading activities to the relevant authorities [10] Miscellaneous - The system will be executed in accordance with current laws and regulations, and the board of directors holds the interpretation rights [11]

Core Points - The company aims to enhance the quality of information disclosure and ensure the authenticity, accuracy, completeness, timeliness, and consistency of its external information disclosure [1][2] - The information disclosure system is established in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] - The company has a continuous responsibility for information disclosure and must treat all shareholders fairly, ensuring equal access to significant information [2][3] Information Disclosure Principles - Information disclosure must be timely, fair, and accurate, avoiding any misleading statements or omissions [3][4] - The company must control the knowledge of undisclosed significant information to a minimum and prevent insider trading [4][5] - If significant undisclosed information leaks or if there are abnormal stock trading activities, the company must take immediate action and report to the Shanghai Stock Exchange [4][5] Types of Disclosure Documents - The main types of disclosure documents include prospectuses, fundraising documents, listing announcements, periodic reports, and temporary reports [2][3] - The company must ensure that all disclosed information is consistent across different platforms and must not use complex jargon or ambiguous expressions [4][5] Periodic Reports - The company is required to disclose annual, semi-annual, and quarterly reports, which must be audited by qualified accounting firms [11][12] - The annual report must be completed and disclosed within four months after the end of each fiscal year, while the semi-annual report must be disclosed within two months after the end of the first half of the fiscal year [11][12] Major Events and Temporary Reports - The company must immediately disclose any major events that could significantly impact stock prices or investor decisions [41][42] - Major events include significant financial losses, legal issues, or changes in management that could affect the company's operations [42][43] Industry Information and Risks - The company must proactively disclose industry information that could significantly impact stock prices or investor decisions [62][63] - It is required to disclose potential risks that could adversely affect its core competitiveness and operational activities [67][68]

Core Viewpoint - The internal audit system of Shanghai MicroPort MedBot (Group) Co., Ltd. aims to enhance corporate governance, standardize economic behavior, improve audit quality, and protect shareholders' rights [1][2]. Group 1: Internal Audit Definition and Objectives - Internal audit is defined as an independent evaluation of the effectiveness of internal controls, risk management, and the authenticity of financial information [1]. - The objectives of internal control include compliance with laws, improving operational efficiency, safeguarding assets, and ensuring accurate information disclosure [1][2]. Group 2: Structure and Responsibilities - The company establishes an audit committee under the board of directors, with a majority of independent directors, including at least one accounting professional [2][3]. - An internal audit department is set up to oversee the authenticity of financial information and the implementation of internal control systems, reporting directly to the audit committee [2][3]. Group 3: Audit Procedures and Requirements - The internal audit department must draft an annual audit plan based on the company's specific circumstances [5]. - Audit procedures include issuing audit notifications, reviewing financial documents, and ensuring the reliability of audit evidence [5][6]. Group 4: Evaluation and Reporting - The internal audit department is responsible for evaluating the effectiveness of internal controls and must submit an internal control evaluation report at least annually [8][9]. - The company must disclose any significant internal control deficiencies or risks identified during audits, along with corrective measures taken [9][11]. Group 5: Incentives and Disciplinary Measures - The company implements an incentive and restraint mechanism for the internal audit department, rewarding outstanding performance and reporting of illegal activities [10]. - Disciplinary actions are outlined for both audited units and internal audit personnel in cases of violations or misconduct [10][12].

Group 1 - The core viewpoint of the article highlights the financial performance of Xinmai Medical, indicating a decline in revenue and profit for the first half of 2025 compared to the previous year [1] - Xinmai Medical reported an operating income of approximately 714 million yuan, a year-on-year decrease of 9.24% [1] - The net profit attributable to shareholders was about 315 million yuan, reflecting a year-on-year decrease of 22.03% [1] - Basic earnings per share were 2.55 yuan, down 22.02% year-on-year [1] - As of the report, Xinmai Medical's market capitalization stood at 14.6 billion yuan [1] Group 2 - The article also mentions a significant growth opportunity in the pet industry, which is projected to reach a market size of 300 billion yuan, indicating a booming sector with rising interest from listed companies [1]

Core Viewpoint - Shanghai MicroPort Endovascular Medical Technology (Group) Co., Ltd. reported a significant decrease in revenue and net profit for the first half of 2025 compared to the same period in 2024, alongside a proposed cash dividend distribution to shareholders [1][4]. Financial Performance - Total revenue for the first half of 2025 was approximately 714.43 million yuan, a decrease of 9.24% compared to 787.17 million yuan in the same period of 2024 [4]. - Net profit attributable to shareholders was approximately 270.83 million yuan, down 29.96% from 386.65 million yuan year-on-year [4]. - The cash dividend proposed is 13.00 yuan per 10 shares, amounting to a total distribution of approximately 236.82 million yuan, which represents 75.26% of the net profit for the first half of 2025 [1]. Shareholder Information - As of July 31, 2025, the total number of shares was 123,262,117, with 2,178,271 shares held in a repurchase account [1]. - The largest shareholder, MicroPort Endovascular China Corp. Limited, holds 39.77% of the shares [5]. Asset Overview - Total assets at the end of the reporting period were approximately 4.60 billion yuan, reflecting a 7.29% increase from 4.29 billion yuan at the end of the previous year [2].

[Important Notice and Profit Distribution Plan](index=2&type=section&id=Important%20Notice%20and%20Profit%20Distribution%20Plan) This report confirms the semi-annual report's integrity, highlights major risks, and details the 2025 semi-annual profit distribution plan, including a 13.00 yuan cash dividend per 10 shares - The report is unaudited, and all directors attended the board meeting, declaring the financial report to be true, accurate, and complete[5](index=5&type=chunk) - The company has detailed potential risks in Section III "Management Discussion and Analysis", "IV. Risk Factors" of this report[4](index=4&type=chunk) 2025 Semi-Annual Profit Distribution Plan | Indicator | Amount/Ratio | | :--- | :--- | | Cash Dividend per 10 Shares (tax incl.) (yuan) | 13.00 | | Total Proposed Cash Dividend (tax incl.) (yuan) | 157,408,999.80 | | Total Cash Dividend and Repurchase Amount (yuan) | 236,817,953.61 | | As % of H1 2025 Net Profit Attributable to Parent | 75.26% | | Total Cash Dividend and Repurchase and Cancellation Amount (yuan) | 157,408,999.80 | | As % of H1 2025 Net Profit Attributable to Parent | 50.03% | [Section I Definitions](index=5&type=section&id=Section%20I%20Definitions) This section defines common and professional terms, including company names, regulatory bodies, medical technologies, and policies, for clear report understanding - Common terms include company and related party names such as "CardioFlow Medical", "Shanghai Lanmai", "MicroPort Medical", and regulatory and certification terms like "NMPA" and "CE Certificate"[13](index=13&type=chunk) - Professional terms cover anatomical concepts like "aorta", "thoracic aorta", "abdominal aorta", "aortic arch", "peripheral vessels", and medical technologies and policies such as "aortic dissection", "TEVAR procedure", "TIPS", and "DRGs payment policy"[13](index=13&type=chunk)[14](index=14&type=chunk) [Section II Company Profile and Key Financial Indicators](index=6&type=section&id=Section%20II%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section outlines company basics, stock info, and key financial indicators for H1 2025, noting a year-on-year decline in revenue and net profit [I. Company Basic Information](index=6&type=section&id=I.%20Company%20Basic%20Information) This section details the company's registration, contact information, stock overview, and information disclosure channels - The company's full name is Shanghai MicroPort CardioFlow Medical Technology (Group) Co., Ltd., abbreviated as CardioFlow Medical, with Zhu Qing as its legal representative[16](index=16&type=chunk) - The company's stock code is **688016**, listed on the STAR Market of the Shanghai Stock Exchange[20](index=20&type=chunk) - The company's information disclosure newspapers are China Securities Journal, Shanghai Securities News, Securities Times, and Securities Daily, with the semi-annual report available at http://www.sse.com.cn[19](index=19&type=chunk) [II. Key Accounting Data and Financial Indicators](index=7&type=section&id=II.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) H1 2025 saw revenue, total profit, and net profit decline, with basic and diluted EPS also decreasing, alongside reduced ROE and R&D intensity Key Accounting Data (Jan-Jun 2025 vs Prior Period) | Indicator | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (yuan) | 714,429,779.98 | 787,174,656.18 | -9.24 | | Total Profit (yuan) | 366,935,691.12 | 471,155,238.14 | -22.12 | | Net Profit Attributable to Listed Company Shareholders (yuan) | 314,647,223.94 | 403,523,612.05 | -22.03 | | Net Cash Flow from Operating Activities (yuan) | 318,603,321.20 | 342,138,859.57 | -6.88 | Key Financial Indicators (Jan-Jun 2025 vs Prior Period) | Indicator | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic EPS (yuan/share) | 2.55 | 3.27 | -22.02 | | Diluted EPS (yuan/share) | 2.55 | 3.27 | -22.02 | | Weighted Average ROE (%) | 8.16 | 10.15 | Decrease by 1.99 percentage points | | R&D Investment as % of Operating Revenue (%) | 8.85 | 11.98 | Decrease by 3.13 percentage points | Balance Sheet Data (Current Period End vs Prior Year End) | Indicator | Current Period End | Prior Year End | Change (%) | | :--- | :--- | :--- | :--- | | Net Assets Attributable to Listed Company Shareholders (yuan) | 4,030,319,620.37 | 3,791,843,035.70 | 6.29 | | Total Assets (yuan) | 4,604,264,927.34 | 4,291,597,451.31 | 7.29 | [III. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=8&type=section&id=III.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) There are no differences in the company's accounting data under domestic and overseas accounting standards during the reporting period - There are no differences in the company's accounting data under domestic and overseas accounting standards[24](index=24&type=chunk) [IV. Non-Recurring Gains and Losses Items and Amounts](index=8&type=section&id=IV.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) This section lists H1 2025 non-recurring gains and losses, totaling 43,821,611.68 yuan, primarily from government grants and financial asset fair value changes Non-Recurring Gains and Losses Items and Amounts | Non-Recurring Gains and Losses Item | Amount (yuan) | | :--- | :--- | | Government Grants Recognized in Current Profit/Loss | 44,905,553.42 | | Fair Value Changes and Disposal Gains/Losses from Financial Assets/Liabilities Held by Non-Financial Enterprises (Excluding Effective Hedging Related to Normal Operations) | 7,659,856.97 | | Non-Current Asset Disposal Gains/Losses | -3,956.26 | | Other Non-Operating Income and Expenses Apart from the Above | -170,595.42 | | Less: Income Tax Impact | 7,325,665.13 | | Minority Interest Impact (After Tax) | 1,243,581.90 | | **Total** | **43,821,611.68** | [V. Net Profit After Deducting Share-Based Payment Impact (Optional for Companies with Equity Incentive/Employee Stock Ownership Plans)](index=9&type=section&id=V.%20Net%20Profit%20After%20Deducting%20Share-Based%20Payment%20Impact%20(Optional%20for%20Companies%20with%20Equity%20Incentive%2FEmployee%20Stock%20Ownership%20Plans)) Net profit attributable to shareholders after deducting share-based payment impact for H1 2025 was 322,883,294.70 yuan, a 21.64% year-on-year decrease Net Profit After Deducting Share-Based Payment Impact | Indicator | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Net Profit After Deducting Share-Based Payment Impact (yuan) | 322,883,294.70 | 412,043,720.68 | -21.64 | [VI. Explanation of Non-GAAP Performance Indicators](index=9&type=section&id=VI.%20Explanation%20of%20Non-GAAP%20Performance%20Indicators) The company has no non-GAAP performance indicators to explain during the reporting period - The company has no non-GAAP performance indicators to explain[28](index=28&type=chunk) [Section III Management Discussion and Analysis](index=9&type=section&id=Section%20III%20Management%20Discussion%20and%20Analysis) This section discusses the company's industry, operations, core competencies, and risks, noting leading market position but declining H1 revenue and profit due to market changes [I. Industry and Main Business Overview During the Reporting Period](index=9&type=section&id=I.%20Industry%20and%20Main%20Business%20Overview%20During%20the%20Reporting%20Period) The company leads in aortic and peripheral vascular interventional devices, expanding globally, but H1 2025 revenue and profit declined due to market and pricing adjustments - The company's main business covers R&D, production, sales, and services of aortic and peripheral vascular interventional medical devices, committed to providing medical solutions for blood circulation diseases[29](index=29&type=chunk) - The company has a comprehensive product portfolio and leading scale in aortic interventional medical devices, successfully developing several domestically first-of-its-kind or globally first products, such as Castor® Branched Aortic Stent Graft[29](index=29&type=chunk)[30](index=30&type=chunk) - In H1 2025, Cratos® Bran

格隆汇8月26日｜心脉医疗公告，2025年上半年营业收入7.14亿元，同比下降9.24%。净利润3.15亿元， 同比下降22.03%。公司拟向全体股东每10股派发现金红利13元（含税），拟派发现金红利总额为1.57亿 元（含税）。现金分红和回购金额合计2.37亿元，占2025年上半年归属于上市公司股东净利润的比例为 75.26%。 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-032 上海微创心脉医疗科技（集团）股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况专 项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）印发的《上市公 司募集资金监管规则》（证监会公告[2025]10号）、《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》等相关法律法规的规定及要求，上海 微创心脉医疗科技（集团）股份有限公司（以下简称"公司"、"本公司"或"心脉 医疗"）董事会将公司2025年半年度募集资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 （一）实际募集资金情况 1、2019年首次公开发行股票 根据上海微创心脉医疗科技（集团）股份有限公司2019年3月12日召开的第 一届董事会第三次会议决议和2019年3月27日召开的2019年第一次临时股东大会 决议，并于2019年7月2日经中国证券监督管理委员会《关于同意上海微创心脉医 疗科技股份有限公司首次公开 ...

上海微创心脉医疗科技（集团）股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年 度评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，践行"以投资者为本" 的上市公司发展理念，推动上海微创心脉医疗科技（集团）股份有限公司（以下 简称"公司"）持续优化经营、规范治理和积极回报投资者，大力提高公司质量， 助力信心提振、资本市场稳定和经济高质量发展，基于对公司未来发展前景的信 心、对公司价值的认可和切实履行社会责任，公司于 2025 年 3 月 29 日发布了 《2025 年度"提质增效重回报"专项行动方案》，以进一步提升公司经营效率， 强化市场竞争力，保障投资者权益，稳定股价，树立良好的资本市场形象。现对 公司 2025 年度"提质增效重回报"行动方案半年度实施情况及效果进行评估总结， 具体如下： 一、聚焦主动脉及外周血管介入领域，巩固提升核心竞争力 报告期内，公司实现营业总收入 71,442.98 万元，比上年同期下降 9.24%； 营业成本 22,013.40 万元，比上年同期增长 19.37%；销售费用、管理费用与上年 同期相比分别增加了 53.68%、32.00%，主要由于收购整合 L ...